Li Kang Biomedical Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Li Kang Biomedical.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Personal Products earnings growth | 18.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Li Kang Biomedical (GTSM:6242) Has Some Way To Go To Become A Multi-Bagger
Apr 19
Is Li Kang Biomedical Co., Ltd. (GTSM:6242) A Smart Choice For Dividend Investors?
Mar 09Li Kang Biomedical Co., Ltd.'s (GTSM:6242) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Feb 09The Trends At Li Kang Biomedical (GTSM:6242) That You Should Know About
Jan 19We Think Li Kang Biomedical (GTSM:6242) Can Stay On Top Of Its Debt
Dec 29Three Things You Should Check Before Buying Li Kang Biomedical Co., Ltd. (GTSM:6242) For Its Dividend
Dec 08In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Li Kang Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 573 | 82 | 67 | 81 | N/A |
| 6/30/2024 | 572 | 84 | 60 | 73 | N/A |
| 3/31/2024 | 597 | 95 | 73 | 79 | N/A |
| 12/31/2023 | 629 | 111 | 93 | 97 | N/A |
| 9/30/2023 | 653 | 116 | 98 | 101 | N/A |
| 6/30/2023 | 712 | 129 | 162 | 164 | N/A |
| 3/31/2023 | 739 | 126 | 167 | 170 | N/A |
| 12/31/2022 | 684 | 112 | 155 | 157 | N/A |
| 9/30/2022 | 622 | 98 | 148 | 149 | N/A |
| 6/30/2022 | 498 | 73 | 81 | 84 | N/A |
| 3/31/2022 | 395 | 55 | 60 | 65 | N/A |
| 12/31/2021 | 387 | 51 | 56 | 60 | N/A |
| 9/30/2021 | 419 | 61 | 42 | 46 | N/A |
| 6/30/2021 | 514 | 79 | 89 | 93 | N/A |
| 3/31/2021 | 482 | 75 | 105 | 107 | N/A |
| 12/31/2020 | 457 | 69 | 80 | 82 | N/A |
| 9/30/2020 | 429 | 60 | 83 | 84 | N/A |
| 6/30/2020 | 371 | 46 | 44 | 44 | N/A |
| 3/31/2020 | 436 | 59 | 51 | 51 | N/A |
| 12/31/2019 | 483 | 72 | 92 | 93 | N/A |
| 9/30/2019 | 468 | 70 | 78 | 79 | N/A |
| 6/30/2019 | 477 | 72 | 31 | 86 | N/A |
| 3/31/2019 | 506 | 75 | 36 | 113 | N/A |
| 12/31/2018 | 496 | 77 | 28 | 106 | N/A |
| 9/30/2018 | 517 | 86 | 37 | 117 | N/A |
| 6/30/2018 | 518 | 137 | N/A | 125 | N/A |
| 3/31/2018 | 498 | 139 | N/A | 116 | N/A |
| 12/31/2017 | 496 | 134 | N/A | 111 | N/A |
| 9/30/2017 | 485 | 127 | N/A | 98 | N/A |
| 6/30/2017 | 472 | 72 | N/A | 101 | N/A |
| 3/31/2017 | 458 | 66 | N/A | 115 | N/A |
| 12/31/2016 | 451 | 62 | N/A | 111 | N/A |
| 9/30/2016 | 440 | 55 | N/A | 89 | N/A |
| 6/30/2016 | 439 | 54 | N/A | 70 | N/A |
| 3/31/2016 | 455 | 55 | N/A | 47 | N/A |
| 12/31/2015 | 456 | 53 | N/A | 64 | N/A |
| 9/30/2015 | 444 | 12 | N/A | 78 | N/A |
| 6/30/2015 | 400 | 14 | N/A | 106 | N/A |
| 3/31/2015 | 306 | -9 | N/A | 74 | N/A |
| 12/31/2014 | 256 | -26 | N/A | 42 | N/A |
| 9/30/2014 | 205 | -13 | N/A | 19 | N/A |
| 6/30/2014 | 214 | -33 | N/A | -23 | N/A |
| 3/31/2014 | 220 | -58 | N/A | -18 | N/A |
| 12/31/2013 | 237 | -62 | N/A | -23 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6242's forecast earnings growth is above the savings rate (1.1%).
Earnings vs Market: Insufficient data to determine if 6242's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 6242's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 6242's revenue is forecast to grow faster than the TW market.
High Growth Revenue: Insufficient data to determine if 6242's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6242's Return on Equity is forecast to be high in 3 years time